Effects of ICL670 (deferasirox) on cardiac iron concentrations

被引：17

作者：

Kontoghiorghes, G ^{[1
]}

机构：

[1] Postgrad Res Inst Sci Technol Environm & Med, CY-3021 Limassol, Cyprus

来源：

LANCET | 2005年 / 366卷 / 9488期

关键词：

D O I：

10.1016/S0140-6736(05)67205-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：804 / 804

页数：1

相关论文

共 5 条

[1] Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2*cardiovascular magnetic resonance [J].

Anderson, LJ ;

Westwood, MA ;

Holden, S ;

Davis, B ;

Prescott, E ;

Wonke, B ;

Porter, JB ;

Walker, JM ;

Pennell, DJ .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (03) :348-355

[2] Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade®) versus deferoxamine in patients with β-thalassemia and transfusional hemosiderosis [J].

Cappellini, M ;

Bejaoui, M ;

Perrotta, S ;

Agaoglu, L ;

Kattamis, A ;

Giardina, P ;

Janka-Schaub, G ;

Opitz, H ;

Ressayre-Djaffer, C ;

Alberti, D .

BLOOD, 2004, 104 (11) :984A-984A

[3] ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture [J].

Hershko, C ;

Konijn, AM ;

Nick, HP ;

Breuer, W ;

Cabantchik, ZI ;

Link, G .

BLOOD, 2001, 97 (04) :1115-1122

[4] Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia [J].

Kolnagou, A ;

Fessas, C ;

Papatryphonas, A ;

Economides, C ;

Kontoghiorghes, GJ .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (03) :360-361

[5] Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia:: a randomised, double-blind, placebo-controlled, dose-escalation trial [J].

Nisbet-Brown, E ;

Olivieri, NF ;

Giardina, PJ ;

Grady, RW ;

Neufeld, EJ ;

Séchaud, R ;

Krebs-Brown, AJ ;

Anderson, JR ;

Alberti, D ;

Sizer, KC ;

Nathan, DG .

LANCET, 2003, 361 (9369) :1597-1602